A swift big pharma endorsement for Kiadis
Shortly after canning its lead and acquiring the NK cell company Cytosen, Kiadis flips part of the tech to Sanofi.
Roche and Lilly most vested in research
The world’s largest drug companies splashed out a record $78bn on R&D last year, with Roche and Lilly the biggest spenders.
Covid-19 vaccines remain hot – in spite of Inovio
Biontech and Pfizer come roaring back with the first human data on BNT162, a day after Inovio’s effort disappointed.
Sanofi’s third Translate collaboration sees big bucks at last
The deal-hungry French big pharma gives Translate’s mRNA vaccine technology a massive boost.
Third-quarter events to watch for large drug makers
Biogen’s aducanumab filing is keenly awaited, as are clinical data from Sanofi, Bristol Myers Squibb, Lilly and others.
Big pharma sports smallest late-stage pipeline for a decade
The number of novel, pivotal-stage projects in big pharma pipelines has plunged – just as Covid-19 put the brakes on deal making.
AAD 2020 – Leo’s eczema wildcard proves tame
Dupixent might face a threat to its lead in dermatitis – but this comes from Pfizer, not Leo.
US FDA approval tracker: several early decisions in May
Last month the FDA greenlit four oncology approvals early and the first GnRH antagonist in uterine fibroids.
Merck joins Covid-19 pack with vaccine and antiviral deals
Merck & Co might have got off to a slow start, but now hopes to make up for lost time with multiple projects.
